This follow-up to my post on the technical reasons why biogenerics are so hard to regulate provides some updates the […]
The commercial prospects of biogenerics – how much will they save? Read Post »
If there’s one sure rule about private equity, it is that there are no rules about private equity! Venture capitalists
Biotechnology companies have been facing a widening funding gap. Between frozen federal research budgets and a growing focus among venture
The United States is the world’s largest pharmaceutical market. Japan is the second largest, although the combined European Union is
Countries use various methods to control drug expenditures. Beyond simple negotiation, countries can also implement price controls or use WTO-authorized
Price controls and compulsory licensing give buyers more power … for a price. Read Post »
Investing and Clinical Trials PharmaGossip has an illuminating excerpt from The End of Medicine describing a method to invest in
There’s been a lot of press floating around lately about the push to develop a framework for biogeneric (or biosimilar,
I’ve been invited to join the editorial board of the nascent Open Biotechnology Journal. The Open Biotechnology Journal is a
Scientific Advances The MaRS Blog has a captivating story of Canada’s recent major diabetes discovery. The first discovery, in 1920,
This edition of the Carnival of Biotechnology features a number of posts on distressing industry trends, some enlightening patent discussion,